Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
A1BG Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
23 July 2026
A visual target evaluation report for A1BG, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Small fiber neuropathy Indication Strategy Report 2026: Nav1.7, Trials and Deals
23 July 2026
2026 Small fiber neuropathy strategy: epidemiology, Nav1.7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Chemotherapy-induced peripheral neuropathy Indication Strategy Report 2026: Nav1.7, Trials and Deals
23 July 2026
2026 Chemotherapy-induced peripheral neuropathy strategy: epidemiology, Nav1.7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Complex regional pain syndrome Indication Strategy Report 2026: NGF, Trials and Deals
23 July 2026
2026 Complex regional pain syndrome strategy: epidemiology, NGF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Postherpetic neuralgia Indication Strategy Report 2026: Nav1.7, Trials and Deals
23 July 2026
2026 Postherpetic neuralgia strategy: epidemiology, Nav1.7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hemiplegic migraine Indication Strategy Report 2026: CACNA1A, Trials and Deals
23 July 2026
2026 Hemiplegic migraine strategy: epidemiology, CACNA1A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Chronic migraine Indication Strategy Report 2026: CGRP, Trials and Deals
23 July 2026
2026 Chronic migraine strategy: epidemiology, CGRP biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Transverse myelitis Indication Strategy Report 2026: IL-6R, Trials and Deals
23 July 2026
2026 Transverse myelitis strategy: epidemiology, IL-6R biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Optic neuritis Indication Strategy Report 2026: C5, Trials and Deals
23 July 2026
2026 Optic neuritis strategy: epidemiology, C5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Anti-NMDA receptor encephalitis Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Anti-NMDA receptor encephalitis strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Miller Fisher syndrome Indication Strategy Report 2026: C5, Trials and Deals
23 July 2026
2026 Miller Fisher syndrome strategy: epidemiology, C5 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Guillain-Barré syndrome Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Guillain-Barré syndrome strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.